CO2021008845A2 - Conotoxin Peptide Analogs and Uses for Pain and Inflammatory Conditions - Google Patents

Conotoxin Peptide Analogs and Uses for Pain and Inflammatory Conditions

Info

Publication number
CO2021008845A2
CO2021008845A2 CONC2021/0008845A CO2021008845A CO2021008845A2 CO 2021008845 A2 CO2021008845 A2 CO 2021008845A2 CO 2021008845 A CO2021008845 A CO 2021008845A CO 2021008845 A2 CO2021008845 A2 CO 2021008845A2
Authority
CO
Colombia
Prior art keywords
peptide analogs
conotoxin peptide
pain
inflammatory conditions
conotoxin
Prior art date
Application number
CONC2021/0008845A
Other languages
Spanish (es)
Inventor
Jose Mercado
Eric J Tarcha
Jeffrey J Posakony
Shawn Iadonato
Original Assignee
Kineta Chronic Pain Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kineta Chronic Pain Llc filed Critical Kineta Chronic Pain Llc
Publication of CO2021008845A2 publication Critical patent/CO2021008845A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

En el presente documento se proporcionan análogos de péptidos de alfa-conotoxina, los cuales incluyen a los análogos de péptidos de alfa-conotoxina que se unen de una forma covalente al polietilen glicol (PEG), y composiciones farmacéuticas de tales análogos de péptidos de alfa-conotoxina. También se proporcionan en este documento los métodos para tratar o prevenir una afección propicia para el tratamiento o la prevención por medio de la inhibición de un receptor de acetilcolina nicotínico (nAChR) que contiene α9 (por ejemplo, el subtipo α9α10 del nAChR) en un sujeto.Provided herein are alpha-conotoxin peptide analogs, which include alpha-conotoxin peptide analogs that bind covalently to polyethylene glycol (PEG), and pharmaceutical compositions of such alpha peptide analogs. -conotoxin. Also provided herein are methods of treating or preventing a condition conducive to treatment or prevention by inhibiting a nicotinic acetylcholine receptor (nAChR) containing α9 (eg, the α9α10 nAChR subtype) in a subject.

CONC2021/0008845A 2019-01-04 2021-07-02 Conotoxin Peptide Analogs and Uses for Pain and Inflammatory Conditions CO2021008845A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2019/012307 WO2020142102A1 (en) 2019-01-04 2019-01-04 Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions

Publications (1)

Publication Number Publication Date
CO2021008845A2 true CO2021008845A2 (en) 2021-10-29

Family

ID=65244618

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0008845A CO2021008845A2 (en) 2019-01-04 2021-07-02 Conotoxin Peptide Analogs and Uses for Pain and Inflammatory Conditions

Country Status (15)

Country Link
EP (1) EP3906253A1 (en)
JP (1) JP2022522935A (en)
KR (1) KR20210116505A (en)
CN (1) CN113966339A (en)
AU (1) AU2019418319A1 (en)
BR (1) BR112021013302A2 (en)
CA (1) CA3125383A1 (en)
CL (1) CL2021001775A1 (en)
CO (1) CO2021008845A2 (en)
CR (1) CR20210363A (en)
IL (1) IL284574A (en)
MX (1) MX2021008070A (en)
PE (1) PE20211734A1 (en)
SG (1) SG11202106847SA (en)
WO (1) WO2020142102A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230033485A (en) 2021-09-01 2023-03-08 삼성전자주식회사 Storage device and operating method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9717775B2 (en) * 2006-07-18 2017-08-01 University Of Utah Research Foundation Methods for treating pain and screening analgesic compounds
US9284358B2 (en) 2006-07-18 2016-03-15 University Of Utah Research Foundation Conotoxin peptides
WO2009126292A2 (en) * 2008-04-08 2009-10-15 Aileron Therapeutics, Inc. Biologically active peptidomimetic macrocycles
WO2016073949A1 (en) * 2014-11-07 2016-05-12 Kineta Three, Llp Modifications and uses of conotoxin peptides

Also Published As

Publication number Publication date
AU2019418319A1 (en) 2021-07-22
BR112021013302A2 (en) 2021-09-14
CL2021001775A1 (en) 2022-05-27
SG11202106847SA (en) 2021-07-29
WO2020142102A1 (en) 2020-07-09
KR20210116505A (en) 2021-09-27
IL284574A (en) 2021-08-31
MX2021008070A (en) 2021-10-13
JP2022522935A (en) 2022-04-21
EP3906253A1 (en) 2021-11-10
CA3125383A1 (en) 2020-07-09
CN113966339A (en) 2022-01-21
CR20210363A (en) 2021-12-10
WO2020142102A9 (en) 2020-11-19
PE20211734A1 (en) 2021-09-06

Similar Documents

Publication Publication Date Title
PE20190910A1 (en) THERAPEUTIC COMPOUNDS USEFUL FOR THE PROPHYLACTIC OR THERAPEUTIC TREATMENT OF AN INFECTION WITH THE HIV VIRUS
DOP2019000201A (en) HIV INHIBITING COMPOUNDS
ECSP22023220A (en) MONO OR DISUBSTITUTED INDOL DERIVATIVES AS INHIBITORS OF DENGUE VIRAL REPLICATION
MX2020004467A (en) Methods for treating or preventing asthma by administering an il-4r antagonist.
DOP2021000195A (en) TRICYCLIC BRIDGE CARBAMOYL PYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE
RU2017116740A (en) COMBINATIONS FOR THE TREATMENT OF MULTIPLE SCLEROSIS
BR112016020199A8 (en) human plasma kallikrein inhibitor compound, pharmaceutical composition comprising said compound, kit and its use
UY36465A (en) CARBAMOILPIRIDONE POLICYCLY COMPOUNDS AND THEIR PHARMACEUTICAL USE
CO2018009563A2 (en) Indoline derivatives substituted as inhibitors of dengue viral replication
DOP2016000254A (en) PHARMECEUTIC FORMULATIONS OF PAN-RAF QUINASE INHIBITOR, PROCEDURES FOR THEIR PREPARATION, AND METHODS OF USE.
CY1124773T1 (en) TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING AT LEAST AMITRIPTYLINE FOR THE THERAPEUTIC TREATMENT OF PERIPHERAL NEUROPATHIC ALGAE
DOP2017000049A (en) TRICYCLIC COMPOUNDS CONTAINING NITROGEN FOR THE TREATMENT OF INFECTION BY NEISSERIA GONORRHOEAE
EA201991387A1 (en) TRICYCLIC JONES - PYRIMIDINE DERIVATIVES FOR INHIBITING ROR-γ AND OTHER APPLICATIONS
CL2021001388A1 (en) Useful compounds in hiv therapy
BR112016024176A2 (en) oral care compositions having improved stability
EA201790495A1 (en) PHARMACEUTICAL COMPOSITIONS OF LONG-TERM ACTION
CL2021002309A1 (en) Useful compounds in hiv therapy
UY37449A (en) ANTI-CHIKV ANTIBODIES AND USES OF THESE
CL2021002107A1 (en) Triamterene or nolatrexed for use in the treatment of phenylketonuria.
CO2021008845A2 (en) Conotoxin Peptide Analogs and Uses for Pain and Inflammatory Conditions
EA201991531A1 (en) METHODS OF TREATMENT OF LINACLOTIDE COMPOSITIONS WITH DELAYED DELIVERY
AR099299A1 (en) INHIBITOR OF THE CHOLESTERILE ESTER TRANSFER PROTEIN (CETP) AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE SUCH INHIBITOR FOR USE IN THE TREATMENT OR PREVENTION OF CARDIOVASCULAR DISEASES
BR112019008698A2 (en) method for treating cancer in a subject who needs it and pharmaceutical composition
AR113727A1 (en) CONOTOXIN PEPTIDE ANALOGUES AND USES FOR THE TREATMENT OF PAIN AND INFLAMMATORY CONDITIONS
EA201892837A1 (en) PHYSIOLOGICALLY BALANCED COMPOUNDS FOR INJECTIONS, INCLUDING PHOSNET SUPPORTANT